Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

NCT03569475 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

501

Enrollment

INDUSTRY

Sponsor class

Conditions

Major Depressive Disorder

Interventions

DRUG: Levomilnacipran ER
DRUG: Fluoxetine
DRUG: Placebo

Sponsor

Allergan